The bills, which have advanced in the Senate, would require schools to take certain preventative measures to protect student health in the classroom and on the athletic field.

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...

The company unveiled plans last week to test its GLP-1/glucagon dual receptor agonist in alcohol use disorder and ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

OPKO Health (OPK) and Entera Bio (ENTX) entered into a collaboration and license agreement to advance into the clinic the first oral dual ...

Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with better graft and patient survival among kidney transplant recipients with diabetes, according to a study published online ...

Glucagon like peptide medications also known as GLP-1s is a medicine group that helps lower blood sugar in people with diabetes. It can also help with weight loss in some ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

On the other hand, when your blood sugar levels drop too low, your pancreas releases the hormone glucagon, which raises your blood sugar levels. Some people, such as those with diabetes ...

SFC Fluidics, Inc. ("SFC") and Duracell U.S. Operations, Inc. ("Duracell") are collaborating to efficiently deliver power to SFC's dual-hormone insulin and glucagon delivery pod. The goal of this ...